Research Reports | Market Assessment
February 2017

Breast Cancer | Unmet Need | US/EU: Advanced/Metastatic Triple-Negative Breast Cancer | 2017

There are limited treatment options for patients with advanced/metastatic, triple-negative breast cancer because commonly used treatments in other breast cancer segments (i.e., hormonal therapies and HER2-targeted therapies) are ineffective in this disease subset. Hence, a high unmet need exists for efficacious targeted therapies for this patient population. Several novel therapies are in development for advanced/metastatic, triple-negative breast cancer; however, historically, it has been difficult for agents to improve outcomes for this hard-to-treat population. Our content examines key drivers of prescribing in this indication and analyses of significant commercial opportunities.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports